| Status: Superseded | ||
AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE ISSUED JUNE 2017. Refer to TA449: Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease for full guidance on NICE recommendations, including any specific restrictions on the use of the technology. AWMSG documentation provided for reference only. |
||
|
||
Medicine details |
||
| Medicine name | everolimus (Afinitor®) | |
| Formulation | 2.5 mg, 5 mg and 10 mg tablet | |
| Reference number | 1872 | |
| Indication | Treatment of unresectable or metastatic, well-differentiated (Grade 1 or Grade 2) non-functional neuroendocrine tumours of gastrointestinal or lung origin in adults with progressive disease |
|
| Company | Novartis Pharmaceuticals UK Ltd | |
| BNF chapter | Malignant disease & immunosuppression | |
| Assessment type | Non-submission | |
| Status | Superseded | |
| Ratification by Welsh Government | 29/09/2016 | |
| Date of issue | 30/09/2016 | |
| NICE guidance | ||